Agreed, but with Excellegen alone when you look at the potential in the US and now in China, the revenue would be amazing. Then add on AE37 and then the vaccine.

I just can't see not looking at this in anything but in a positive light. While the vaccine is still a work in progress, Excellegen is a product that they do currently have, so that can already be marketed, AE37 has already been through one trial, so they have a one up on that already. So, this should be looked at as a big step forward.